Continuous glucose monitoring during intravenous insulin infusion treatment: Assessing accuracy to enable future clinical utility
Authors' conclusion
This real-world study of adults with T1D demonstrated high concordance of CGM measures with BG during IVII. The accuracy of CGM during IVII might enable its greater clinical utility when treating inpatients receiving IVII. More inpatient studies are required to validate the use of CGM during IVII.
Study context
- Population
- Adults with T1D requiring IV insulin infusion during hospital admission whilst wearing their own continuous glucose monitoring (CGM) devices; 52% with DKA, 32% requiring ICU
- Participants
- 56 hospital admissions
- Exposure
- CGM glucose vs reference blood glucose (BG) during IV insulin infusion
- Outcome
- CGM accuracy: MARD and Consensus error grid analysis of time-matched (±5 minutes) CGM-reference BG pairs
- Follow-up
- During IV insulin infusion
Methodological detailsmulti-centre, real-world, IV insulin dose adjustments based on standard of care BG measures
- Multi-centre
- Real-world
- IV insulin dose adjustments based on standard of care BG measures
Main finding
As reported in the abstract
MARD
Overall mean absolute relative difference (MARD)
12.5%
MARD, CGM-POC pairs
11.9%
MARD, CGM-GAS pairs
14.1%
Glucose pairs within Consensus error grid zones A/B
99.0%
Observational data: associations, not effects.
Further findings
Dose adjustments same if CGM used instead of POC (local non-ICU ward protocols)
- Dose adjustments would have been the same
- 77%
IV insulin infusion duration
- Median IV insulin infusion duration (IQR 7.2-28)
- 16 hours
Original publication
Continuous glucose monitoring during intravenous insulin infusion treatment: Assessing accuracy to enable future clinical utility. Diabet Med. Published 21 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →